Adaptimmune Therapeutics plc

Designing and delivering cell therapies to transform the lives of people with cancer.  

Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers

Learn More

<
>

Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022

Learn More

<
>

Watch the replay of our Live Virtual Event on Adaptimmune’s SURPASS Family of Trials

Watch Replay

<
>

Designing and delivering cell therapies to transform the lives of people with cancer.

ASCO press release - clinical responses reported across patient subgroups with afami-cel, confirming potential for people with rare sarcomas

Press Release

<
>

Designing and delivering cell therapies to transform the lives of people with cancer.

We presented two posters with preclinical proof-of-concept data supporting future clinical development at ASGCT Annual Meeting 2022

Press Release
Visit ADP-A2M4N7X19 poster
Visit ADP-TILIL7 poster

<
>

Designing and delivering cell therapies to transform the lives of people with cancer.

Identifying MAGE-A4-Positive Tumors for SPEAR T-Cell Therapies in HLA-A*02—Eligible Patients

Press Release
Poster

<
>
Designing and delivering cell therapies to transform the lives of people with cancer.  

Adaptimmune’s mission is to transform the lives of people with cancer by designing and delivering cell therapies

Learn More
<
>
Our Clinical Trials

Advancing T-cell therapy through world-class expertise

Our main priority at Adaptimmune is to improve the outcomes of patients who are suffering from cancer via immunotherapy.

View Our Clinical Trials
For Patients and Families

Helpful resources for patients and their families

Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.

View Our Resources
Our Pipeline

SPEAR-heading the Cancer Revolution

An industry leading TCR pipeline that targets solid tumors

We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.

View Our Pipeline

Our Robust Manufacturing Process

Delivering affinity-enhanced TCRs to patients

Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.

Learn More

Latest News

Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent

Read Press Release View All Press Releases

Corporate Deck

November 2022 Corporate Deck

View Presentation View All Presentations